New drug trial targets specific genetic flaw in blood cancer
NCT ID NCT04409639
Summary
This study is testing if the drug cobimetinib can help control a specific type of blood cancer called Chronic Myelomonocytic Leukemia (CMML) in adults. It is for people who are newly diagnosed or whose previous treatment has stopped working, and whose cancer has specific genetic changes. Participants take the drug daily in repeating cycles to see if it reduces the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutchinson Cancer Research Center
Seattle, Washington, 98109, United States
-
Huntsman Cancer Institute at University of Utah
Salt Lake City, Utah, 84112, United States
-
Oregon Health and Science University
Portland, Oregon, 97239, United States
Conditions
Explore the condition pages connected to this study.